epoprostenol - CISMeF

Preferred Label : epoprostenol;

MeSH definition : A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).;

MeSH synonym : prostaglandin i2; prostacyclin; prostaglandin i(2); epoprostanol;

CISMeF synonym : 61849-14-7 (Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-Isomer);

CISMeF acronym : pgi2; pgx;

MeSH hyponym : flolan; epoprostenol sodium; Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer;

MeSH CAS label : Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-;

MeSH Related Number : 35121-78-9 (Epoprostenol); epoprostenol sodium; 4K04IQ1OF4;

Registry Number MeSH : 35121-78-9;

Related CAS MeSH : 4K04IQ1OF4 (Epoprostenol sodium);

MeSH annotation : /chem syn permitted: do not convert to PROSTAGLANDINS, SYNTHETIC; DF: PGX;

Wikipedia link : https://en.wikipedia.org/wiki/Prostacyclin;

Is substance : O;

UNII : DCR9Z582X0;

InChIKey : KAQKFAOMNZTLHT-OZUDYXHBSA-N;

Details

Origin ID

D011464;

UMLS CUI

C0033567;

ATC code(s)
- epoprostenol [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- deficiency [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Epoprostenol adverse reaction (disorder) [SNOMED CT concept]
Indexing information
- RS 93427-007 [MeSH Supplementary Concept]
Pharmacological action(s)
- antihypertensive agents [MeSH Descriptor]
- platelet aggregation inhibitors [MeSH Descriptor]
Record concept(s)
- epoprostenol [MeSH concept]
- epoprostenol sodium [MeSH concept]
- flolan [MeSH concept]
- veletri [MeSH concept]
Related MeSH Supplementary Concept(s)
- 10,10-difluoro-13-dehydroprostacyclin [MeSH Supplementary Concept]
- 11-desoxyprostacyclin [MeSH Supplementary Concept]
- 13,14-dehydroprostaglandin I2 [MeSH Supplementary Concept]
- 13,14-dehydroprostaglandin I2 methyl ester [MeSH Supplementary Concept]
- 13,14-didehydro-20-methylcarboprostacyclin [MeSH Supplementary Concept]
- 13,14-dinor-inter-p-phenylene carbacyclin [MeSH Supplementary Concept]
- 15-cyclopentyl-7-oxo-prostaglandin I2-ephedrine [MeSH Supplementary Concept]
- 15-deoxy-(16-m-tolyl)-17,18,19,20-tetranorisocarbacyclin methylester [MeSH Supplementary Concept]
- 15-deoxy-16-m-tolyl-17,18,19,20-tetranorisocarbacyclin [MeSH Supplementary Concept]
- 15-fluoro-13,14-dehydrocarbacyclin [MeSH Supplementary Concept]
- 15-ketoprostaglandin I2 [MeSH Supplementary Concept]
- 16-tolyl-17,18,19,20-tetranorisocarbacyclin [MeSH Supplementary Concept]
- 17,20-dimethylisocarbacyclin [MeSH Supplementary Concept]
- 19-(3-azidophenyl)-20-norisocarbacyclin [MeSH Supplementary Concept]
- 2,2,10,10-tetrafluoro-13-dehydroprostacyclin [MeSH Supplementary Concept]
- 20-methyl-13,14-didehydro-2,4-inter-3-phenylene prostaglandin I2 [MeSH Supplementary Concept]
- 3-oxa-9(O)-methano-delta(6,9)prostaglandin I(1) [MeSH Supplementary Concept]
- 3-oxacarbacyclin [MeSH Supplementary Concept]
- 3-oxahomoisocarbacyclin [MeSH Supplementary Concept]
- 4,5-didehydroisocarbacyclin [MeSH Supplementary Concept]
- 5,6-dihydroprostacyclin [MeSH Supplementary Concept]
- 5-hydroxyprostaglandin I [MeSH Supplementary Concept]
- 5-methyleneisocarbacyclin [MeSH Supplementary Concept]
- 5-nitroprostaglandin I1 [MeSH Supplementary Concept]
- 5-nitroprostaglandin I2 [MeSH Supplementary Concept]
- 6,9-thiaprostacyclin [MeSH Supplementary Concept]
- 6a-carbaprostaglandin I3 [MeSH Supplementary Concept]
- 7-fluoroprostacyclin [MeSH Supplementary Concept]
- 7-oxo-cyclopentyl-prostaglandin I2 [MeSH Supplementary Concept]
- 7-oxo-prostaglandin I2-ephedrine [MeSH Supplementary Concept]
- 7-oxoprostaglandin I2 [MeSH Supplementary Concept]
- 7a-homo-2-norprostacyclin [MeSH Supplementary Concept]
- 9-O-methanoprostaglandin I [MeSH Supplementary Concept]
- AFP 03 [MeSH Supplementary Concept]
- AFP 06 [MeSH Supplementary Concept]
- AFP 07 [MeSH Supplementary Concept]
- APS 306 [MeSH Supplementary Concept]
- CG 4303 [MeSH Supplementary Concept]
- CL 115999 [MeSH Supplementary Concept]
- FCE 21258 [MeSH Supplementary Concept]
- HOE 892 [MeSH Supplementary Concept]
- KAG-308 [MeSH Supplementary Concept]
- KP 10614 [MeSH Supplementary Concept]
- MM 706 [MeSH Supplementary Concept]
- OP 2507 [MeSH Supplementary Concept]
- OP 41483-alpha-cyclodextrin [MeSH Supplementary Concept]
- PFC-Kyoto solution [MeSH Supplementary Concept]
- R 59274 [MeSH Supplementary Concept]
- SC 39902 [MeSH Supplementary Concept]
- SM 10902 [MeSH Supplementary Concept]
- SM 10906 [MeSH Supplementary Concept]
- TEI 1324 [MeSH Supplementary Concept]
- TEI 3356 [MeSH Supplementary Concept]
- TEI 4343 [MeSH Supplementary Concept]
- TEI 9090 [MeSH Supplementary Concept]
- TFC 132 [MeSH Supplementary Concept]
- TRY 200 [MeSH Supplementary Concept]
- TTC 909 [MeSH Supplementary Concept]
- TY 10957 [MeSH Supplementary Concept]
- TY 11223 [MeSH Supplementary Concept]
- U 56467 [MeSH Supplementary Concept]
- U 68215 [MeSH Supplementary Concept]
- U 72382 [MeSH Supplementary Concept]
- ataprost [MeSH Supplementary Concept]
- benzodioxane prostacyclin [MeSH Supplementary Concept]
- beraprost [MeSH Supplementary Concept]
- bicyclo(4.3.0)non-2-ene homoisocarbacyclin [MeSH Supplementary Concept]
- carboprostacyclin [MeSH Supplementary Concept]
- chinoin 7284 [MeSH Supplementary Concept]
- chinoin 7384 [MeSH Supplementary Concept]
- cicaprost [MeSH Supplementary Concept]
- ciprostene [MeSH Supplementary Concept]
- dehydro-15-cyclohexylcarbaprostacyclin [MeSH Supplementary Concept]
- dihomo-prostaglandin I(2) [MeSH Supplementary Concept]
- hexadecyl-treprostinil [MeSH Supplementary Concept]
- homoisocarbacyclin [MeSH Supplementary Concept]
- naxaprostene [MeSH Supplementary Concept]
- nileprost [MeSH Supplementary Concept]
- nitriloprostaglandin I2 [MeSH Supplementary Concept]
- osaka university cocktail [MeSH Supplementary Concept]
- piriprost [MeSH Supplementary Concept]
- prostaglandin I2 11-methyl ether [MeSH Supplementary Concept]
- prostaglandin I2 15-methyl ether [MeSH Supplementary Concept]
- prostaglandin I2 methyl ester [MeSH Supplementary Concept]
- prostaglandin I3 [MeSH Supplementary Concept]
- taprostene [MeSH Supplementary Concept]
- tilsuprost [MeSH Supplementary Concept]
- treprostinil [MeSH Supplementary Concept]
See also inter- (CISMeF)
- sodium (5z,13e,15s)-6,9.alpha.-epoxy-11.alpha.,15-dihydroxyprosta-5,13-dien-1-oate [Substance BNPC]
Semantic type(s)
- Biologically Active Substance [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Epoprostenol [ICD-11 Extension code]
- Epoprostenol [NCIt concept]
- Epoprostenol (substance) [SNOMED CT concept]
- Product containing epoprostenol (medicinal product) [SNOMED CT concept]
- epoprostenol [ATC Code]
- prostaglandin pgi2 [SNOMED Notion]
- prostaglandin x [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients